Pharmacogenetics in early drug development for non-alcoholic steatohepatitis: missed chances and future opportunities-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacogenetics in early drug development for non-alcoholic steatohepatitis: missed chances and future opportunities

Published:2023-05-06 Issue:6 Volume:97 Page:1825-1827
ISSN:0340-5761
Container-title:Archives of Toxicology
language:en
Short-container-title:Arch Toxicol

Author:

Boeckmans Joost^ORCID,Gatzios Alexandra^ORCID,Schattenberg Jörn M.^ORCID,Rodrigues Robim M.^ORCID,Rogiers Vera^ORCID,Vanhaecke Tamara^ORCID

Funder

Research Foundation Flanders

Society of Toxicology - Colgate-Palmolive

Chair Mireille Aerens for the Development of Alternative Methods

Publisher

Springer Science and Business Media LLC

Subject

Health, Toxicology and Mutagenesis,Toxicology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00204-023-03498-0.pdf

Reference25 articles.

1. Amangurbanova M, Huang DQ, Loomba R (2023) Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD. Aliment Pharmacol Ther 57:37–51. https://doi.org/10.1111/apt.17292

2. Boeckmans J, Natale A, Rombaut M et al (2020) Anti-NASH drug development hitches a lift on PPAR agonism. Cells 9:1–20. https://doi.org/10.3390/cells9010037

3. Boeckmans J, Natale A, Rombaut M et al (2021) Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. Cell Biol Toxicol 37:293–311. https://doi.org/10.1007/s10565-020-09544-2

4. Boeckmans J, Gatzios A, Schattenberg JM et al (2023) PNPLA3 I148M and response to treatment for hepatic steatosis: a systematic review. Liver Int. https://doi.org/10.1111/liv.15533

5. Cherubini A, Casirati E, Tomasi M, Valenti L (2021) PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opin Ther Targets 25:1033–1043. https://doi.org/10.1080/14728222.2021.2018418

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3